Open Access

Liposome encapsulated luteolin showed enhanced antitumor efficacy to colorectal carcinoma

  • Authors:
    • Guixia Wu
    • Jing Li
    • Jinqiao Yue
    • Shuying Zhang
    • Kurexi Yunusi
  • View Affiliations

  • Published online on: November 29, 2017     https://doi.org/10.3892/mmr.2017.8185
  • Pages: 2456-2464
  • Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Luteolin is a falconoid compound that is present in various types of plants and possesses remarkable potential as a chemopreventive agent. However, the poor aqueous solubility of luteolin limits its clinical application. In the present study, an approach towards chemoprevention was explored using liposomes to deliver luteolin, and the antitumor efficacy was investigated in colorectal carcinoma. The present findings demonstrated that luteolin was efficiently encapsulated into liposomes with an encapsulation efficiency as high as 90%. The particle size of the liposomal luteolin (Lipo‑Lut) and ζ‑potential were optimized. In vitro studies demonstrated that, Lipo‑Lut had a significant inhibitory effect on the growth on the CT26 colorectal carcinoma cell line compared with free luteolin (Free‑Lut). The in vivo study indicated that Lipo‑Lut could achieve superior antitumor effects against CT26 tumor compared with luteolin alone. The present results suggested that liposome delivery of luteolin improved solubility, bioavailability and may have potential applications in chemoprevention in clinical settings.

References

1 

Yang C, Liu HZ, Fu ZX and Lu WD: Oxaliplatin long-circulating liposomes improved therapeutic index of colorectal carcinoma. BMC Biotechnol. 11:212011. View Article : Google Scholar : PubMed/NCBI

2 

Nobili S, Checcacci D, Filippelli F, Del Buono S, Mazzocchi V, Mazzei T and Mini E: Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. J Chemother. 20:622–631. 2008. View Article : Google Scholar : PubMed/NCBI

3 

Chen AY and Chen YC: A review of the dietary flavonoid, kaempferol on human health and cancer chemoprevention. Food Chem. 138:2099–2107. 2013. View Article : Google Scholar : PubMed/NCBI

4 

Majumdar D, Jung KH, Zhang H, Nannapaneni S, Wang X, Amin AR, Chen Z, Chen ZG and Shin DM: Luteolin nanoparticle in chemoprevention: In vitro and in vivo anticancer activity. Cancer Prev Res (Phila). 7:65–73. 2014. View Article : Google Scholar : PubMed/NCBI

5 

Sporn MB, Dunlop NM, Newton DL and Smith JM: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc. 35:pp. 1332–1338. 1976; PubMed/NCBI

6 

Madhunapantula SV and Robertson GP: Chemoprevention of melanoma. Adv Pharmacol. 65:361–398. 2012. View Article : Google Scholar : PubMed/NCBI

7 

Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR and Berry DP: Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis. Eur J Cancer Prev. 18:13–25. 2009. View Article : Google Scholar : PubMed/NCBI

8 

Khor TO, Yu S and Kong AN: Dietary cancer chemopreventive agents-targeting inflammation and Nrf2 signaling pathway. Planta Med. 74:1540–1547. 2008. View Article : Google Scholar : PubMed/NCBI

9 

Kaur M, Singh RP, Gu M, Agarwal R and Agarwal C: Grape seed extract inhibits in vitro and in vivo growth of human colorectal carcinoma cells. Clin Cancer Res. 12:6194–6202. 2006. View Article : Google Scholar : PubMed/NCBI

10 

Kaur M, Velmurugan B, Tyagi A, Agarwal C, Singh RP and Agarwal R: Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of beta-catenin-dependent signaling. Neoplasia. 12:415–424. 2010. View Article : Google Scholar : PubMed/NCBI

11 

Benbrook DM, Guruswamy S, Wang Y, Sun Z, Mohammed A, Zhang Y, Li Q and Rao CV: Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity. Cancer Prev Res (Phila). 6:908–916. 2013. View Article : Google Scholar : PubMed/NCBI

12 

Yang MY, Wang CJ, Chen NF, Ho WH, Lu FJ and Tseng TH: Luteolin enhances paclitaxel-induced apoptosis in human breast cancer MDA-MB-231 cells by blocking STAT3. Chem Biol Interact. 213:60–68. 2014. View Article : Google Scholar : PubMed/NCBI

13 

Huang X, Dai S, Dai J, Xiao Y, Bai Y, Chen B and Zhou M: Luteolin decreases invasiveness, deactivates STAT3 signaling and reverses interleukin-6 induced epithelial-mesenchymal transition and matrix metalloproteinase secretion of pancreatic cancer cells. Onco Targets Ther. 8:2989–3001. 2015. View Article : Google Scholar : PubMed/NCBI

14 

Yan M, Liu Z, Yang H, Li C, Chen H, Liu Y, Zhao M and Zhu Y: Luteolin decreases the UVA-induced autophagy of human skin fibroblasts by scavenging ROS. Mol Med Rep. 14:1986–1992. 2016. View Article : Google Scholar : PubMed/NCBI

15 

Lee HZ, Yang WH, Bao BY and Lo PL: Proteomic analysis reveals ATP-dependent steps and chaperones involvement in luteolin-induced lung cancer CH27 cell apoptosis. Eur J Pharmacol. 642:19–27. 2010. View Article : Google Scholar : PubMed/NCBI

16 

Ong CS, Zhou J, Ong CN and Shen HM: Luteolin induces G1 arrest in human nasopharyngeal carcinoma cells via the Akt-GSK-3β-cyclin D1 pathway. Cancer Lett. 298:167–175. 2010. View Article : Google Scholar : PubMed/NCBI

17 

Chiu FL and Lin JK: Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts. Prostate. 68:61–71. 2008. View Article : Google Scholar : PubMed/NCBI

18 

Cai X, Ye T, Liu C, Lu W, Lu M, Zhang J, Wang M and Cao P: Luteolin induced G2 phase cell cycle arrest and apoptosis on non-small cell lung cancer cells. Toxicol In Vitro. 25:1385–1391. 2011. View Article : Google Scholar : PubMed/NCBI

19 

Balyan R, Kudugunti SK, Hamad HA, Yousef MS and Moridani MY: Bioactivation of luteolin by tyrosinase selectively inhibits glutathione S-transferase. Chem Biol Interact. 240:208–218. 2015. View Article : Google Scholar : PubMed/NCBI

20 

Liu JF, Ma Y, Wang Y, Du ZY, Shen JK and Peng HL: Reduction of lipid accumulation in HepG2 cells by luteolin is associated with activation of AMPK and mitigation of oxidative stress. Phytother Res. 25:588–596. 2011. View Article : Google Scholar : PubMed/NCBI

21 

Abdel Hadi L, Di Vito C, Marfia G, Ferraretto A, Tringali C, Viani P and Riboni L: Sphingosine kinase 2 and ceramide transport as key targets of the natural flavonoid luteolinto induce apoptosis in colon cancer cells. PLoS One. 10:e01433842015. View Article : Google Scholar : PubMed/NCBI

22 

Wölfle U, Esser PR, Simon-Haarhaus B, Martin SF, Lademann J and Schempp CM: UVB-induced DNA damage, generation of reactive oxygen species and inflammation are effectively attenuated by the flavonoid luteolin in vitro and in vivo. Free Radic Biol Med. 50:1081–1093. 2011. View Article : Google Scholar : PubMed/NCBI

23 

Liu Y, Wang L, Zhao Y, He M, Zhang X, Niu M and Feng N: Nanostructured lipid carriers versus microemulsions for delivery of the poorly water-soluble drug luteolin. Int J Pharm. 476:169–177. 2014. View Article : Google Scholar : PubMed/NCBI

24 

Yuan Y, Zhao Y, Xin S, Wu N, Wen J, Li S, Chen L, Wei Y, Yang H and Lin S: A novel PEGylated liposome-encapsulated SANT75 suppresses tumor growth through inhibiting hedgehog signaling pathway. PLoS One. 8:e602662013. View Article : Google Scholar : PubMed/NCBI

25 

Fetterly GJ, Grasela TH, Sherman JW, Dul JL, Grahn A, Lecomte D, Fiedler-Kelly J, Damjanov N, Fishman M and Kane MP: Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel. Clin Cancer Res. 14:5856–5863. 2008. View Article : Google Scholar : PubMed/NCBI

26 

Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A and Barenholz Y: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54:987–992. 1994.PubMed/NCBI

27 

Guo L, Fan L, Ren J, Pang Z, Ren Y, Li J, Wen Z, Qian Y, Zhang L and Ma H: Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer. Int J Nanomedicine. 7:1449–1460. 2012.PubMed/NCBI

28 

Li LT, Jiang G, Chen Q and Zheng JN: Ki67 is a promising molecular target in the diagnosis of cancer (Review). Mol Med Rep. 11:1566–1572. 2015.PubMed/NCBI

29 

Koudelka S, Turanek Knotigova P, Masek J, Prochazka L, Lukac R, Miller AD, Neuzil J and Turanek J: Liposomal delivery systems for anti-cancer analogues of vitamin E. J Control Release. 207:59–69. 2015. View Article : Google Scholar : PubMed/NCBI

30 

Barenholz Y: Doxil® - the first FDA-approved nano-drug: Lessons learned. J Control Release. 160:117–134. 2012. View Article : Google Scholar : PubMed/NCBI

31 

Schiffelers RM, Metselaar JM, Fens MH, Janssen AP, Molema G and Storm G: Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. Neoplasia. 7:118–127. 2005. View Article : Google Scholar : PubMed/NCBI

32 

Gabizon A and Martin F: Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs. 4 Suppl 54:S15–S21. 1997. View Article : Google Scholar

33 

Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L and Winer E; TLC D-99 Study Group, : Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 94:25–36. 2002. View Article : Google Scholar : PubMed/NCBI

34 

Hioki A, Wakasugi A, Kawano K, Hattori Y and Maitani Y: Development of an in vitro drug release assay of PEGylated liposome using bovine serum albumin and high temperature. Biol Pharm Bull. 33:1466–1470. 2010. View Article : Google Scholar : PubMed/NCBI

35 

Deshpande PP, Biswas S and Torchilin VP: Current trends in the use of liposomes for tumor targeting. Nanomedicine (Lond). 8:1509–1528. 2013. View Article : Google Scholar : PubMed/NCBI

36 

Haley B and Frenkel E: Nanoparticles for drug delivery in cancer treatment. Urol Oncol. 26:57–64. 2008. View Article : Google Scholar : PubMed/NCBI

37 

Cukierman E and Khan DR: The benefits and challenges associated with the use of drug delivery systems in cancer therapy. Biochem Pharmacol. 80:762–770. 2010. View Article : Google Scholar : PubMed/NCBI

38 

Fan Y, Liu J, Wang D, Song X, Hu Y, Zhang C, Zhao X and Nguyen TL: The preparation optimization and immune effect of epimedium polysaccharide-propolis flavone liposome. Carbohydr Polym. 94:24–30. 2013. View Article : Google Scholar : PubMed/NCBI

39 

Zhu Y, Wang M, Zhang J, Peng W, Firempong CK, Deng W, Wang Q, Wang S, Shi F, Yu J, et al: Improved oral bioavailability of capsaicin via liposomal nanoformulation: Preparation, in vitro drug release and pharmacokinetics in rats. Arch Pharm Res. 38:512–521. 2014. View Article : Google Scholar : PubMed/NCBI

40 

Pandurangan AK and Esa NM: Luteolin, a bioflavonoid inhibits colorectal cancer through modulation of multiple signaling pathways: A review. Asian Pac J Cancer Prev. 15:5501–5508. 2014. View Article : Google Scholar : PubMed/NCBI

41 

Wang LM, Xie KP, Huo HN, Shang F, Zou W and Xie MJ: Luteolin inhibits proliferation induced by IGF-1 pathway dependent ERα in human breast cancer MCF-7 cells. Asian Pac J Cancer Prev. 13:1431–1437. 2012. View Article : Google Scholar : PubMed/NCBI

42 

Pratheeshkumar P, Son YO, Budhraja A, Wang X, Ding S, Wang L, Hitron A, Lee JC, Kim D, Divya SP, et al: Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. PLoS One. 7:e522792012. View Article : Google Scholar : PubMed/NCBI

43 

Matsumura Y and Maeda H: A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46:6387–6392. 1986.PubMed/NCBI

44 

Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, et al: Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer research campaign phase I/II committee. Clin Cancer Res. 5:83–94. 1999.PubMed/NCBI

Related Articles

Journal Cover

February 2018
Volume 17 Issue 2

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wu, G., Li, J., Yue, J., Zhang, S., & Yunusi, K. (2018). Liposome encapsulated luteolin showed enhanced antitumor efficacy to colorectal carcinoma. Molecular Medicine Reports, 17, 2456-2464. https://doi.org/10.3892/mmr.2017.8185
MLA
Wu, G., Li, J., Yue, J., Zhang, S., Yunusi, K."Liposome encapsulated luteolin showed enhanced antitumor efficacy to colorectal carcinoma". Molecular Medicine Reports 17.2 (2018): 2456-2464.
Chicago
Wu, G., Li, J., Yue, J., Zhang, S., Yunusi, K."Liposome encapsulated luteolin showed enhanced antitumor efficacy to colorectal carcinoma". Molecular Medicine Reports 17, no. 2 (2018): 2456-2464. https://doi.org/10.3892/mmr.2017.8185